Combination immunotherapy better than single agent in head, neck cancer

Karmanos Cancer Institute recognizes April as Head and Neck Cancer Awareness Month

The Barbara Ann Karmanos Cancer Institute, cancer centers, and other organizations nationwide recognize April as Head and Neck Cancer Awareness Month.

Combination immunotherapy better than single agent in head, neck cancer

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 trial.Two different doublets — nivolumab (Opdivo, Bristol Myers Squibb) plus relatlimab (Opdualag, Bristol Myers Squibb), as well as nivolumab plus ipilimumab (Yervoy, Bristol Myers Squibb) —